Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study.

Clin Ophthalmol · 2024 · PMC11606343 · PMID 39618985

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

At six months post-switch, the number of SRF-free eyes decreased slightly to 47 (82.5%), with SRF present in 10 eyes (17.5%); this change also did not reach statistical significance (p = 0.07).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.